Evidence map›Paper›PMID 29126445›Full record

ArticleMolecular neurodegeneration2017

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias.

Franc Llorens, Katrin Thüne, Waqas Tahir, Eirini Kanata, Daniela Diaz-Lucena, Konstantinos Xanthopoulos, Eleni Kovatsi, Catharina Pleschka, Paula Garcia-Esparcia, Matthias Schmitz and 14 more

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 4 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 4 syntheses or guidelines pooled it, 265 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Fluid biomarkers in atypical Parkinsonism: current state and future perspectives.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 4 countries.

Franc LlorensNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Ministry of Health, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. franc.llorens@gmail.com.
Katrin ThüneNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Ministry of Health, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Waqas TahirDepartment of Neurology, University Medical School, Göttingen, Germany.
Eirini KanataLaboratory of Pharmacology, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Daniela Diaz-LucenaNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Ministry of Health, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Konstantinos XanthopoulosLaboratory of Pharmacology, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Eleni KovatsiLaboratory of Pharmacology, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Catharina PleschkaGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Paula Garcia-EsparciaNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Ministry of Health, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Matthias SchmitzDepartment of Neurology, University Medical School, Göttingen, Germany.
Duru OzbayDepartment of Neurology, University Medical School, Göttingen, Germany.
Susana CorreiaDepartment of Neurology, University Medical School, Göttingen, Germany.
Ângela CorreiaDepartment of Neurology, University Medical School, Göttingen, Germany.
Ira MilosevicEuropean Neuroscience Institute, Göttingen, Germany.
Olivier AndréolettiInstitut National de la Recherche Agronomique/Ecole Nationale Vétérinaire, Toulouse, France.
Natalia Fernández-BorgesCentro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain.
Ina M VorbergGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Markus GlatzelInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Theodoros SklaviadisLaboratory of Pharmacology, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Juan Maria TorresCentro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain.
Susanne KrasemannInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Raquel Sánchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Isidro FerrerNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Institute Carlos III, Ministry of Health, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Inga ZerrDepartment of Neurology, University Medical School, Göttingen, Germany.
University of Göttingen · DEBiomedical Research Networking Center on Neurodegenerative Diseases · ESAristotle University of Thessaloniki · GRCentro de Investigación en Sanidad AnimalGerman Center for Neurodegenerative Diseases · DEUniversität Hamburg · DEConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESÉcole Nationale Vétérinaire de Toulouse · FREuropean Neuroscience Institute Göttingen · DE

Funding

Ciberned BESAD-PDAAD - IKYDA 57260006MINECO AGL2015-71764-REDTSpanish Ministry of Health - Instituto Carlos III/Fondo Social Europeo CP16/00041
6 · The paper itself

Abstract

backgroundYKL-40 (also known as Chitinase 3-like 1) is a glycoprotein produced by inflammatory, cancer and stem cells. Its physiological role is not completely understood but YKL-40 is elevated in the brain and cerebrospinal fluid (CSF) in several neurological and neurodegenerative diseases associated with inflammatory processes. Yet the precise characterization of YKL-40 in dementia cases is missing.

methodsIn the present study, we comparatively analysed YKL-40 levels in the brain and CSF samples from neurodegenerative dementias of different aetiologies characterized by the presence of cortical pathology and disease-specific neuroinflammatory signatures.

resultsYKL-40 was normally expressed in fibrillar astrocytes in the white matter. Additionally YKL-40 was highly and widely expressed in reactive protoplasmic cortical and perivascular astrocytes, and fibrillar astrocytes in sporadic Creutzfeldt-Jakob disease (sCJD). Elevated YKL-40 levels were also detected in Alzheimer's disease (AD) but not in dementia with Lewy bodies (DLB). In AD, YKL-40-positive astrocytes were commonly found in clusters, often around β-amyloid plaques, and surrounding vessels with β-amyloid angiopathy; they were also distributed randomly in the cerebral cortex and white matter. YKL-40 overexpression appeared as a pre-clinical event as demonstrated in experimental models of prion diseases and AD pathology. CSF YKL-40 levels were measured in a cohort of 288 individuals, including neurological controls (NC) and patients diagnosed with different types of dementia. Compared to NC, increased YKL-40 levels were detected in sCJD (p < 0.001, AUC = 0.92) and AD (p < 0.001, AUC = 0.77) but not in vascular dementia (VaD) (p > 0.05, AUC = 0.71) or in DLB/Parkinson's disease dementia (PDD) (p > 0.05, AUC = 0.70). Further, two independent patient cohorts were used to validate the increased CSF YKL-40 levels in sCJD. Additionally, increased YKL-40 levels were found in genetic prion diseases associated with the PRNP-D178N (Fatal Familial Insomnia) and PRNP-E200K mutations.

conclusionsOur results unequivocally demonstrate that in neurodegenerative dementias, YKL-40 is a disease-specific marker of neuroinflammation showing its highest levels in prion diseases. Therefore, YKL-40 quantification might have a potential for application in the evaluation of therapeutic intervention in dementias with a neuroinflammatory component.

Indexed as

AgedAnimalsBiomarkersBrainCerebrospinal FluidChitinase-3-Like Protein 1DementiaFemaleHumansMaleMiceMice, TransgenicMiddle AgedNeurodegenerative DiseasesBiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1BrainCerebrospinal fluidChitinase 3-like 1Neurodegenerative dementiasNeuroinflammationYKL-40

Identifiers

PMID29126445
PMCPMC5681777
OpenAlexW2767733203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.